Highlights

HLBank Research Highlights

Author: HLInvest   |   Latest post: Fri, 22 Jan 2021, 10:33 AM

 

Pharmaniaga - Weak quarter

Author:   |    Publish date:


Pharmaniaga’s 3QFY20 core PATMI of RM4.4m (-68% QoQ, -63.7% YoY) brought 9MFY20 core PATMI to RM44.6m (+8.3% YoY). The results came in below ours and consensus’ estimates due to lower than expected revenue contribution (-12% YoY). We cut our FY20-22 profit forecasts by 8-10% to reflect weaker sales. We rollover our valuation to FY21 and post earnings adjustments, our TP falls to RM5.70 (from RM5.94). Our TP is based on FY21 earnings pegged to P/E multiple of 21.5x (+2SD of 5 year mean). We downgrade the stock to HOLD, as share price has rallied +201% since our Buy upgrade back in 24 Feb; we reckon it is now time to take some money off the table.

Below expectations. 3QFY20 core PATMI of RM4.4m (-68% QoQ, -63.7% YoY) brought 9MFY20’s sum to RM44.6m (+8.3% YoY). Core earnings were achieved after eliminating EIs; impairments, provision of stock obsolescence and forex gains, of - RM2.9m. The results accounts for 65% of ours and consensus estimates. The results shortfall was due to lower-than-expected revenue contribution (-12% YoY).

Dividend. Declared dividend of 1.5 sen per share going ex on 4 Dec 2020. (9MFY20: 10 sen per share vs. 9MFY19: 8.5 sen per share).

QoQ. Revenue of RM624.8m was slightly impacted (-3.2%) due to lower demand from both concession and Indonesia business caused by Covid-19 pandemic that disrupted access to doctors, clinics, pharmacies and hospitals. EBITDA margin fell by 1.3ppts (from 4.7% 2QFY20) despite lower costs (-2.1%). PBT declined (-71.4%) on lower other income (-25%) and interest income (-51.1%). Higher effective tax of 41% (vs. 2QFY20: 33%) also contributed to the decrease in Core PATMI of RM4.4m (-68%).

YoY. Lower revenue contribution (-12.8% YoY) was principally attributed to reduction in demand from both concession and Indonesia business which was affected by Covid19 pandemic. EBITDA margin reduced to 3.4% (from 4.3%) even though costs fell (- 13%). As such, Core PATMI saw a reduction of 63.7%.

YTD. 9MFY20 revenue remained stable at RM2.1bn (-0.7% YoY); contribution from non-concession business were higher this period driven by higher sales of PPE in response to Covid-19 pandemic. Overall PBT improved (+5.8% YoY). Logistics and distribution (L&D) division revenue was flat (-0.8% YoY), while finance cost was lower (-18.7% YoY). Manufacturing division saw a decline in revenue (-8.4% YoY) due to lower take up by Government, further impacted by higher finance costs (+5.7% YoY). Meanwhile Indonesian division reported a loss of RM2.4m that was mostly caused by higher finance costs (+3.5% YoY) which resulted from the ongoing delay in payment from government hospitals. Core PATMI improved to RM44.6m (+8.3%) despite a higher effective tax rate of 32% (vs. 9MFY19: 30%).

Outlook. We anticipate a stronger FY21-22 with potential projections coming from fill and finish process for Covid-19 vaccines as well as the partnership with SERUM on Pneumococcal Conjugate Vaccine (PCV). More information will be shared in the analysts’ briefing later today.

Forecast. We cut our FY20-22 profit forecasts by 8-10% to reflect weaker sales.

Downgrade to HOLD, TP: RM5.70. We roll forward our valuation to FY21, post earnings adjustments, our TP decrease to RM5.70 (from RM5.94). Our TP is based on FY21 earnings pegged to P/E multiple of 21.5x (+2SD of 5 year mean). We downgrade the stock to HOLD, as share price has rallied +201% since our Buy upgrade back in 24 Feb; we reckon it is now time to take some money off the table.

Source: Hong Leong Investment Bank Research - 26 Nov 2020

Share this
Labels: PHARMA

Related Stocks

Chart Stock Name Last Change Volume 
PHARMA 4.93 -0.01 (0.20%) 363,800 

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
View candlestick stock charts with Technical indicators
MQ Affiliate
Be rewarded by being an MQ Affiliate
 
 

564  409  601  26 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 TRIVE-OR 0.0050.00 
 QES 0.38+0.04 
 KSTAR 0.21-0.045 
 DNEX 0.26+0.005 
 BIOHLDG 0.30+0.04 
 DYNACIA 0.120.00 
 LAMBO 0.030.00 
 MCLEAN 0.325+0.095 
 AT 0.180.00 
 VSOLAR 0.040.00 

FEATURED POSTS

1. The Equity Market Index Benchmark in Malaysia CMS
2. Trading Scenarios of Derivatives Bursa Derivatives Education Series
3. Derivatives 101 Bursa Derivatives Education Series
4. Why Trade FKLI? Bursa Derivatives Education Series
5. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!
PARTNERS & BROKERS